Xponance Inc. Has $836,000 Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Xponance Inc. boosted its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 1.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 31,704 shares of the biopharmaceutical company’s stock after purchasing an additional 606 shares during the quarter. Xponance Inc.’s holdings in Royalty Pharma were worth $836,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Inspire Investing LLC grew its holdings in shares of Royalty Pharma by 175.1% in the 1st quarter. Inspire Investing LLC now owns 43,524 shares of the biopharmaceutical company’s stock valued at $1,322,000 after buying an additional 27,701 shares during the period. APG Asset Management US Inc. bought a new stake in shares of Royalty Pharma in the fourth quarter worth about $2,100,000. New Century Financial Group LLC acquired a new stake in shares of Royalty Pharma during the first quarter worth about $1,091,000. Patient Capital Management LLC bought a new position in shares of Royalty Pharma during the 4th quarter valued at about $35,247,000. Finally, Rhenman & Partners Asset Management AB lifted its holdings in shares of Royalty Pharma by 186.5% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 429,697 shares of the biopharmaceutical company’s stock valued at $12,070,000 after purchasing an additional 279,697 shares in the last quarter. Institutional investors own 54.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on RPRX shares. UBS Group cut Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 target price for the company. in a research note on Monday, June 3rd. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group boosted their price objective on shares of Royalty Pharma from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, Morgan Stanley increased their target price on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Royalty Pharma Stock Performance

Shares of RPRX opened at $28.21 on Friday. The stock has a market capitalization of $16.74 billion, a price-to-earnings ratio of 21.05, a PEG ratio of 4.09 and a beta of 0.46. Royalty Pharma plc has a 12 month low of $25.20 and a 12 month high of $31.66. The firm has a fifty day simple moving average of $28.01 and a 200 day simple moving average of $27.91. The company has a current ratio of 9.35, a quick ratio of 9.35 and a debt-to-equity ratio of 0.78.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. The company had revenue of $537.00 million during the quarter, compared to the consensus estimate of $600.83 million. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. During the same period in the prior year, the business posted $0.85 EPS. Research analysts forecast that Royalty Pharma plc will post 4.04 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Friday, August 16th were paid a $0.21 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $0.84 dividend on an annualized basis and a yield of 2.98%. Royalty Pharma’s dividend payout ratio is 62.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.